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1. Introduction 
Erectile dysfunction (ED) is a complex, multifactorial issue commonly affecting men of all 
ages. ED is currently defined as “the inability to achieve and/or maintain penile erection 
sufficient to permit satisfactory sexual intercourse”, and has been associated with such risk 
factors as hypertension, diabetes, alcoholism, smoking, and pelvic surgery [1]. This condition 
has seriously impacted the men’s quality of life. Even though nowadays there are a large 
number of options to treat ED, a considerable number of patients do not answer adequately 
the conventional therapies available. Penile erection is achieved through a neurovascular 
response exhibiting an increase in arterial inflow, relaxation of corporal smooth muscle, and 
restriction of the venous outflow. Relatively recent pharmacological advances, namely oral 
phosphodiesterase-5 (PDE5) inhibitors, have become the first line of treatment in ED. PDE5 
inhibitors allow the patient to achieve a penile erection via the effects on the nitric oxide (NO) 
signaling pathway, which is the principal mediator of corporal smooth muscle relaxation. The 
inhibition of the degradative actions of PDE5 on 3’,5’-cyclic guanosine monophosphate 
(cGMP), the second messenger molecule of NO signaling, lead to an increased bioavailability 
of NO in the corporal smooth muscle thus promoting vasodilation and penile erection. 
However, despite the widespread efficacy of these medications, there are still men for which 
oral PDE5 inhibitors are ineffective. ED in men with diabetes, for example, is typically more 
severe, exhibiting a less effective response to PDE5 inhibitors when compared to non-diabetic 
patients. The vascular injuries that accompanies diabetes is often too damaging to endothelial 
physiology to allow adequate penile erections [4] and thus complicates use of the oral 
medications as treatment for ED. Due to the vast array of potential causes of ED ranging from 
neurogenic and vasculogenic to hormonal issues, there exists a continuing need to address 
these deficiencies in patient management of ED and pursue new treatments. Two avenues 
showing a great deal of promise in ED treatment are gene therapy and stem cell therapy, both 
of which could possibly provide methods to prevent or even cure ED. This chapter will focus 
on recent studies in both gene and stem cell therapies in ED research, with the objective to 
establish that continued scientific exploration into these fields will yield clinically applicable 
approaches to combat this condition.  
2. Gene therapy and ED 
Gene therapy is the introduction of exogenous genetic material into cells that either restores 
or enhances normal cellular function that is defective, or essentially attenuates the functional 
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effects of the mutant genetic phenotypic expression. This is accomplished through the use of 
vectors, which are designed to deliver or transfect a given gene into an organism allowing 
the organism to subsequently reproduce the gene and its protein product. Many different 
types of vectors have been characterized; viral vectors such as retroviruses and 
adenoviruses, cell-based vectors such as myoblasts and endothelial cells, as well as non-viral 
vectors such as plasmid DNA and naked DNA. Viral vectors are commonly used due to 
their high cellular transfection efficiency; however they have been shown to trigger immune 
and inflammatory responses which can reduce their effects [5]. The host’s immune response 
can generate antibodies to the virus being used as vector, prompting destruction of the 
delivery system before it generates a therapeutic effect [1]. Additionally, many of the viruses 
used as vectors do not exhibit tissue specificity, contributing to issues associated with viral 
migration through the systemic circulation to other unwanted tissues or organ systems [1].  
Several molecules have been examined as potential gene therapeutic approaches for ED, 
including vascular endothelial growth factor (VEGF), NO synthase, precalcitonin gene-
related peptide, brain derived neurotrophic factor, and the calcium sensitive potassium 
(maxi-K) channel [5]. The penis is considered to be a well suited structure for gene therapy 
due to its limited blood supply, which would decrease the risks associated with non-target 
infection via the systemic circulation. Its external positioning allows for an ease of 
accessibility for genetic manipulation, and the intracellular transference of the erectile tissue 
response to the delivery by gap junctions of corporal smooth muscle further make gene 
therapy a useful approach as only a proportion of cells are required to be transfected [5]. 
The relatively low turnover rate of vascular smooth muscle cells indicates the potential for 
long term expression of introduced genes and thus would yield an improvement over the 
short term effects of current pharmacological therapies [4]. The role of NO in regulating 
corporal smooth muscle relaxation is a primary area of concern in ED, and consequently a 
great deal of the research examining potential gene therapeutic treatments focuses on ways 
to repair deficient endothelial NO production. [4] 
2.1 eNOS gene therapy 
eNOS, or nitric oxide synthase 3, is an enzyme found in endothelial cells that produces the 
NO required for relaxation of the surrounding smooth muscle. It has been shown in patients 
with ED that a lack of eNOS expression potentiates the difficulties in achieving and 
maintaining adequate penile erection through low bioavailability of NO and subsequent 
increase in vascular tone [4]. There have been several studies examining the role of eNOS 
gene therapy to treat many of the underlying vascular pathologies leading to ED. Champion 
et al. studied the effects of using adenoviral gene transfer of eNOS in an age-related rat 
model of ED. Through the increase in production of eNOS mRNA and subsequent increase 
in protein expression, it was observed that there was a notable increased erectile response to 
cavernous nerve stimulation, PDE5 inibitors, and also acetylcholine post-treatment. Within 
the aged-penis there was also an increase in the presence of cGMP noted. In diabetic rat 
models, intracavernosal pressure recorded during cavernosal nerve stimulation is markedly 
lower when compared to the control animals [1]. Bivalacqua et al. have shown that the use 
of intracavernous eNOS transfection is also a viable therapy, improving both the erectile 
response to cavernous nerve stimulation and the levels of corporal NO in diabetic rat model 
of ED. These findings were assessed in conjunction with the use of a PDE5 inhibitor in the 
www.intechopen.com
 
Gene and Stem Cell Therapy in Erectile Dysfunction 
 
187 
diabetic rat model, and it was observed that when combined with intracavernous eNOS 
transfection the erectile response to the pharmacologic treatment was increased along with 
levels of cGMP in the penis.  
2.2 VEGF gene therapy 
Vascular endothelial growth factor (VEGF) is a multifunctional protein and a critical 
mediator of endothelial and smooth muscle physiology. It stimulates angiogenesis and 
increases vascular permeability as well inhibits apoptosis, and as such it provides a potential 
therapeutic approach for the treatment of ED by increasing NO levels through the 
expansion of penile vasculature [1]. The increase in vasculature would bring about an 
accompanying increase in endothelial cells, thus creating an increase of NO production in 
the target organ. Both VEGF and its receptor flk-1 have been shown to be downregulated in 
certain types of ED [4], suggesting a possible pathological association. There have been 
several studies indicating the potential benefits of VEGF treatment for ED. Intracavernous 
injection of VEGF has been shown to provide a protective effect against hypercholesteremia 
in penile corporal endothelium from an atherosclerotic rabbit model of ED. This protective 
effect of VEGF has also been shown in other models of ED such as those accompanying 
diabetes or in traumatic arteriogenic ED. Additionally, endothelial hypertrophy and 
hyperplasia were observed following intracavernous VEGF protein delivery in another 
hypercholesteremic ED model [4]. It is believed that the anti-apoptotic effects of VEGF are 
associated with this hyperplasia and hypertrophy of endothelial cells, potentially by directly 
inducing anti-apoptotic pathways in the endothelium. Other potentially therapeutic effects 
of VEGF in connection with ED are an increase in the expression of eNOS and a stimulatory 
effect on eNOS phosphorylation.  
Further studies have utilized the data supporting the benefits of VEGF protein introduction 
as a foundation for designing VEGF gene therapy treatments. The goal was that introducing 
VEGF DNA would increase long-term expression of VEGF and ameliorate any deficiencies 
in protein amount, essentially acting as a curative treatment for ED [4]. In a study by Rogers 
et al., an adeno-associated virus was used to transfect VEGF DNA into a model of venogenic 
ED, with resulting active angiogenesis indicated by endothelial cell hypertrophy and 
hyperplasia. A similar study examining VEGF DNA delivery in a venogenic model of ED 
using an adenovirus was shown to increase phosphorylation of eNOS leading to a 
concurrent increase in the bioavailability of NO and recovery of erectile function [10]. VEGF 
introduction has also been examined using a combined gene therapy approach with 
angiopoetin-1, an angiogenic growth factor that promotes the creation of new blood vessels 
from pre-existing vessels. Using an adenovirus for both VEGF and angiopoetin-1 in a 
hypercholesteremic rat model of ED, it was found that the ratio of phosphorylated eNOS to 
total eNOS was markedly higher in animals receiving the gene therapy versus the control 
animals. The combined gene therapy approach was found to increase factor VIII-positive 
endothelial density with a subsequent increase in erectile response to electrical stimulation, 
suggesting the importance of functional endothelium in management of ED. 
2.3 SOD gene therapy 
Another potential target for gene therapy in ED is utilizing superoxide dismutase (SOD) to 
decrease the levels of reactive oxygen species (ROS). Reactive oxygen species have been 
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shown to play a critical role in endothelial cell dysfunction, primarily through the actions of 
superoxide scavenging of NO to form the toxic substance peroxynitrite [4]. Superoxide and 
peroxynitrite create a cascade of ROS formation by uncoupling eNOS within the 
endothelium, decreasing the production of NO and thus impairing erectile function. This 
creation of ROS is exacerbated by the expression of inducible nitric oxide synthase (iNOS) 
during oxidative stress conditions, leading to the production of even more ROS. 
Antioxidants are involved in attenuating the toxic effects of ROS. SOD, found in cells such 
as vascular endothelium, helps to decrease levels of superoxide by catalyzing the 
dismutation of the ROS into hydrogen peroxide and water [4].  
In a study by Bivalacqua et al., intracavernous adenoviral gene transfer of extracellular SOD 
was performed in an age-related rat model of ED in an attempt to decrease the levels of 
ROS. In the rat model there was an observed increase in superoxide production, a decrease 
in cGMP production as well as a decrease in erectile response to cavernous nerve 
stimulation. Additionally, they used nitrotyrosine staining as a measure of oxidative stress 
and found elevated levels in the aged rats. Following transfection of extracellular SOD 
DNA, there was an increase in extracellular SOD mRNA, protein, and activity levels, along 
with an increase in cGMP production. Oxidative stress was again measured using 
nitrotyrosine staining and a decrease was observed post therapeutic treatment. Erectile 
response to cavernous nerve stimulation was also restored, suggesting that the introduction 
of extracellular SOD DNA holds potential a viable gene therapy treatment to combat ED 
resulting from ROS damage to penile endothelium. It has also been shown that ROS play a 
role in diabetes-related vascular dysfunction and also ED [4], prompting studies on the 
effects of extracellular SOD gene therapy in diabetic models of ED. Extracellular SOD 
expression was notably decreased in the diabetic penis, contributing to an increase in the 
levels of ROS present. Adenoviral transfection of extracellular SOD decreased levels of 
superoxide and increased cGMP production, which together improved erectile function in 
an endothelium dependent manner. 
2.4 Anti-arginase gene therapy 
Supplementation of the amino acid L-arginine, either through the diet or direct infusion, has 
been shown to cause an increase in NO and a subsequent enhancement of endothelium-
related vasodilation in the penis [2]. L-Arginine is used as a substrate by both eNOS and 
arginase, the latter of which converts L-arginine to urea and L-ornithine. This creates a 
synergistic relationship between the two enzymes, as an increase in arginase activity leads 
to a downregulation of NO biosynthesis through competition with eNOS [2]. The enzyme 
arginase has two isoforms, arginase I and arginase II. Arginase I and II are commonly 
referred to as the hepatic type and extrahepatic type, respectively, though in a study by 
Bivalacqua et al. which showed an increase in arginase activity in human diabetic corpus 
cavernosum that both arginase isoforms were found. It was suggested that the impaired 
endothelium-derived NO bioactivity or signaling via an increased expression of arginase 
plays a role in the reduction of endothelium-dependant response in the penis of aged mice 
[2]. Utilizing adeno-associated viral gene transfer of anti-arginase, Bivalacqua et al. found 
that there was a decrease of arginase-1 protein and mRNA in the aged mouse penis 
accompanied by restoration of endothelial and erectile function in vivo [2]. The increase in 
erectile function was attributed to the increase in constitutive NOS activity and penile cGMP 
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levels, suggesting that arginase can interfere with normal erectile function by decreasing 
production of endothelium-derived eNOS in the penis. Interestingly, it has been shown that 
in the aged rat penis there is an increase in eNOS protein expression in endothelial cells due 
to a reduction in caveolin-1, a protein that regulates eNOS. This increase in eNOS protein 
expression is accompanied by a significant decrease in eNOS activity, suggesting that the 
upregulated protein is not biologically active. This is supported by the restoration of 
endothelial vascular responses as a result of increased eNOS activity following adeno-
associated viral gene transfer of anti-arginase [2]. While arginase inhibition was shown to 
improve erectile function, it was not shown to fully restore it, suggesting that there are likely 
multifactorial mechanisms of endothelial dependant erectile response impairment. Even 
still, the enhanced penile eNOS activity and cGMP levels resulting from arginase inhibition 
via anti-arginase gene therapy make it a potential molecular therapeutic treatment of age-
associated vasculogenic ED [2]. 
When considering gene therapy as a treatment for ED, there are a number of potential issues 
that need to be taken into consideration. As mentioned previously, there is the risk that viral 
vectors could enter the systemic circulation and thus cause random transgene expression in 
unwanted tissues or organs. Increasing the specificity of viral vectors, such that they could 
target appropriate cells without damaging other cells, could allow for injection systemically 
rather than intracavernously. There are several methods that have been examined by which 
to increase the specificity of the viral vectors such as transcriptional and transductional 
targeting. Transcriptional targeting works through the selection of a cell specific promoter , 
whereas transductional targeting utilizes cell specific membrane markers to induce delivery 
of the genetic material. The risk of an immune response to the commonly studied viral 
vectors is also a concern, as this could hinder use of the therapy in both, acute or repeated 
clinical treatments. To limit the possibility of an unwanted immune and inflammatory 
response, it would be beneficial to lower the necessary load of virus required to transduce 
cells in the penis. Future studies exploring gene therapy for the treatment of ED should look 
to create as normal of an erectile response as possible by maximizing the specificity of the 
treatments as well as decreasing any potential unwanted side effects.  
3. Stem cell therapy and ED 
Stem cells have become increasingly popular as a potential treatment for a wide variety of 
diseases, including ED. Stem cells are defined by the capacity to self renew and differentiate 
into one or more distinct cell types. The stem cell’s potential to differentiate can be 
extensive, being referred to as pluripotent when it can differentiate into any cell type in the 
organism. Other levels of differentiation ranging from multipotent to the more limited 
progenitor cells exist, providing numerous avenues from which potential therapies can be 
pursued. With the advent of induced pluripotential stem cells (iPS cells), scientists now have 
access to a line of pluripotent cells with which to work without many of the moral and 
ethical concerns revolving around the use of human embryonic stem cells. Adult-derived 
stem cells are also an area of current research, utilizing cell types such as mesenchymal stem 
cells and adipose-derived stem cells to replace lost or damaged cells in target tissues [2]. 
Stem cell treatment is attractive as a potential therapy for ED due to the underlying 
multifactorial pathologies responsible for the disease. The ability to replace whole cells 
could correct several of the associated specific molecular pathologies of ED with one type of 
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treatment [2]. Stem cell replacement of penile endothelial cells may allow for recovery of 
normal erectile response, as endothelial dysfunction is one of the primary causes of ED.  
3.1 MSC therapy 
One of the more commonly used adult stem cells is mesenchymal stem cells (MSCs). There 
are produced in the bone marrow, as well as certain other tissues and organs, and they 
possess the ability to differentiate into a wide variety of cell types depending on the 
biological environment [2]. They are able to be isolated and expanded ex vivo, making them 
an advantageous choice for cell therapy [3]. It has been shown previously that MSCs are 
able to differentiate into endothelial and smooth muscle cells to repair vascular injury in 
vivo, making them a viable option for the treatment of vasculogenic ED. In a study by 
Bivalacuqa et al., MSCs were used to differentiate into endothelial cells, thereby improving 
endothelium-derived NO bioavailability and thus erectile physiology. The MSCs were 
injected intracavernously with or without simultaneous eNOS gene therapy, and in both 
groups there was a marked increase in erectile response, eNOS activity, and cGMP levels. 
The MSCS were found to still be present and expressing endothelial and smooth muscle cell 
markers not present before injection twenty-one days post injection, which suggests that the 
differentiated stem cells could provide long term replacement of damaged cells. Other 
studies have also examined the combined use of MSCs and gene therapy. In a recent study 
by Qiu et al., the efficacy of MSCs both alone and in combination with VEGF gene therapy 
for the treatment of ED in a type 1 diabetic rat model was observed. The survival of 
engrafted stem cells in the target tissue is always a concern during treatments, including in 
this study following intracavernous implantation. Survival of MSCs has been shown to 
increase when coupled with VEGF treatment, as noted by the accompanying increase in pro-
survival factors phosphorylated Akt and Bcl-xL. Improved erectile function and an increase 
in the number of endothelial and smooth muscle cells were noted post injection, with the 
rats receiving the combined stem cell and VEGF gene therapy exhibiting the greatest 
increase compared to the animals treated with MSCs alone or the control group [3]. This 
suggests that the use of MSCs is a potential route for stem cell therapy of ED, especially 
when considered with concurrent gene therapeutic treatments.  
3.2 ADSC therapy 
Another type of adult stem cells that has been examined for the treatment of ED is adipose-
derived stem cells (ADSCs). They are found in fat tissue and possess the qualities of stem 
cell, namely self-renewal and differentiation into multiple cell phenotypes, as well as the 
ability to provide functional repair of damaged tissue. In terms of differentiation and 
therapeutic potential, ADSCs are similar to MSCs but are easier and safer to harvest in large 
quantities as adipose tissue is a readily available biological source. ADSCs have been shown 
to be vascular precursor stem cells, making them an appropriate choice for stem cell therapy 
of ED [24]. In a study by Bella et al., the effects of ADSCs to repopulate endothelial and 
smooth muscle cells in erectile tissue following bilateral cavernous nerve crush injury were 
examined. Using intracavernosal pressure (ICP) as a measure of erectile function, the 
animals treated with ADSCs were observed to have higher ICP response and thus a better 
recovery of erectile function when compared with the control animals. The ability of ADSCs 
to help restore erectile function in this study was suggested to result from their 
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differentiation into local penile cell types, as well through the secretion of growth factors 
that recruited local stem cells to differentiate, promoted IGF-1 mediated local functional cell 
growth, and exhibited a neurotrophic effect to promote nerve regeneration [26].  
In another study using ADSCs, Garcia et al. tested the use of ADSCs for the treatment of ED 
in obese type 2 diabetic ZDF rats. These rats were shown previously to have an 85% 
prevalence of impotence (ICP60 cmH2O) among their population, making them an 
appropriate model to test the efficacy of ADSCs to survive in-vivo and subsequently restore 
erectile function. Three weeks after ADSCS injection into the rat penis, there was a noted 
functional improvement in erectile function when compared with untreated animals, as 
indicated by an improvement in ICP. It was determined that the effect of the treatment may 
be a result of an increase in the population of endothelial cells and a decrease in 
intracorporal tissue apoptosis among the treated rats. The survival of the ADSCs was 
assessed using BrdU labeling, which did not indicate the presence of many injected ADSCs 
after three weeks post injection. This suggests that the observed therapeutic effects likely 
result from elaboration of cytokines and growth factors from the ADSCs as opposed to 
direct differentiation in local cell types. An increase in nNOS (NOS type 1) was also seen, 
indicating that there may have been a restorative impact on nitrergic neuron axons and 
ganglia leading to improved erectile function. However, it is also possible that this increase  
 
Fig. 1. Gene and stem cell therapies for the treatment of ED. Gene therapy treatments consist 
of eNOS, VEGF, SOD, and arginase inhibitor vectors. Stem cell therapy treatments include 
adipocyte-derived stem cell (ADSCs) and mesenchymal stem cell (MSCs) introduction into 
the cavernosal tissue. A combined gene therapy and stem cell therapy approach utilizing 
MSCs and VEGF has also been studied. 
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in nNOS was a result of increased oxygenated blood flow supplying more dorsal nerve 
nNOS following erectile function improvement. The use of ADSCs is an attractive 
therapeutic option in future studies, as the ease with which great numbers of cells can be 
harvested eliminates the need for ex vivo cell culture, thereby reducing the risk of 
contamination from a variety of organisms.   
4. Conclusion 
The advent of gene and stem cell therapy has unveiled new horizons for the future of 
medicine and clinical treatments. Among the many potential diseases able to be positively 
altered by these therapeutic treatments, ED has already been shown to be an appropriate 
pathological target. The use of gene and stem cell therapies alone or in combination with 
each other and other treatments such as pharmacological interventions holds great promise 
in the future care of patients afflicted with ED (Figure 1). 
5. References 
[1] Mills, J.N., et al., The molecular basis of erectile dysfunction: from bench to bedside. Reviews in 
urology, 2005. 7(3): p. 128-34. 
[2] Bivalacqua, T.J., et al., Overexpression of arginase in the aged mouse penis impairs erectile 
function and decreases eNOS activity: influence of in vivo gene therapy of anti-arginase. 
American journal of physiology. Heart and circulatory physiology, 2007. 292(3): p. 
H1340-51. 
[3] Qiu, X., et al., Combined Strategy of Mesenchymal Stem Cells Injection with VEGF Gene 
Therapy for the Treatment of Diabetes Associated Erectile Dysfunction. Journal of 
andrology, 2011. 
[4] Strong, T.D., et al., Endothelium-specific gene and stem cell-based therapy for erectile 
dysfunction. Asian journal of andrology, 2008. 10(1): p. 14-22. 
[5] Burnett, A.L., Erectile dysfunction management for the future. Journal of andrology, 2009. 
30(4): p. 391-6. 
[6] Champion, H.C., et al., Gene transfer of endothelial nitric oxide synthase to the lung of the 
mouse in vivo. Effect on agonist-induced and flow-mediated vascular responses. 
Circulation research, 1999. 84(12): p. 1422-32. 
[7] Bivalacqua, T.J., et al., Gene transfer of endothelial nitric oxide synthase partially restores nitric 
oxide synthesis and erectile function in streptozotocin diabetic rats. The Journal of 
urology, 2003. 169(5): p. 1911-7. 
[8] Bivalacqua, T.J., et al., Effect of combination endothelial nitric oxide synthase gene therapy and 
sildenafil on erectile function in diabetic rats. International journal of impotence 
research, 2004. 16(1): p. 21-9. 
[9] Lin, C.S., et al., Intracavernosal injection of vascular endothelial growth factor induces nitric 
oxide synthase isoforms. BJU international, 2002. 89(9): p. 955-60. 
[10] Musicki, B., et al., Phosphorylated endothelial nitric oxide synthase mediates vascular 
endothelial growth factor-induced penile erection. Biology of reproduction, 2004. 70(2): 
p. 282-9. 
www.intechopen.com
 
Gene and Stem Cell Therapy in Erectile Dysfunction 
 
193 
[11] Rogers, R.S., et al., Intracavernosal vascular endothelial growth factor (VEGF) injection  
and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic 
erectile dysfunction in rats. International journal of impotence research, 2003. 15(1): p. 
26-37. 
[12] Ryu, J.K., et al., Combined angiopoietin-1 and vascular endothelial growth factor gene transfer 
restores cavernous angiogenesis and erectile function in a rat model of 
hypercholesterolemia. Molecular therapy : the journal of the American Society of 
Gene Therapy, 2006. 13(4): p. 705-15. 
[13] Xu, J., et al., Oxygen-glucose deprivation induces inducible nitric oxide synthase and 
nitrotyrosine expression in cerebral endothelial cells. Stroke; a journal of cerebral 
circulation, 2000. 31(7): p. 1744-51. 
[14] Bivalacqua, T.J., et al., Gene transfer of extracellular SOD to the penis reduces O2-* and 
improves erectile function in aged rats. American journal of physiology. Heart and 
circulatory physiology, 2003. 284(4): p. H1408-21. 
[15] Bivalacqua, T.J., et al., Superoxide anion production in the rat penis impairs erectile function 
in diabetes: influence of in vivo extracellular superoxide dismutase gene therapy. The 
journal of sexual medicine, 2005. 2(2): p. 187-97; discussion 197-8. 
[16] Bivalacqua, T.J., et al., Increased expression of arginase II in human diabetic corpus 
cavernosum: in diabetic-associated erectile dysfunction. Biochemical and biophysical 
research communications, 2001. 283(4): p. 923-7. 
[17] Bakircioglu, M.E., et al., Decreased trabecular smooth muscle and caveolin-1 expression in the 
penile tissue of aged rats. The Journal of urology, 2001. 166(2): p. 734-8. 
[18] Sadeghi, H. and M.M. Hitt, Transcriptionally targeted adenovirus vectors. Current gene 
therapy, 2005. 5(4): p. 411-27. 
[19] Waehler, R., S.J. Russell, and D.T. Curiel, Engineering targeted viral vectors for gene 
therapy. Nature reviews. Genetics, 2007. 8(8): p. 573-87. 
[20] Wu, X., et al., Mesenchymal stem cells participating in ex vivo endothelium repair and its 
effect on vascular smooth muscle cells growth. International journal of cardiology, 2005. 
105(3): p. 274-82. 
[21] Wang, T., et al., Cell-to-cell contact induces mesenchymal stem cell to differentiate into 
cardiomyocyte and smooth muscle cell. International journal of cardiology, 2006. 
109(1): p. 74-81. 
[22] Bivalacqua, T.J., et al., Mesenchymal stem cells alone or ex vivo gene modified with 
endothelial nitric oxide synthase reverse age-associated erectile dysfunction. American 
journal of physiology. Heart and circulatory physiology, 2007. 292(3): p. H1278-90. 
[23] Pons, J., et al., VEGF improves survival of mesenchymal stem cells in infarcted hearts. 
Biochemical and biophysical research communications, 2008. 376(2): p. 419-22. 
[24] Lin, G., et al., Potential of adipose-derived stem cells for treatment of erectile dysfunction. The 
journal of sexual medicine, 2009. 6 Suppl 3: p. 320-7. 
[25] Garcia, M.M., et al., Treatment of erectile dysfunction in the obese type 2 diabetic ZDF rat 
with adipose tissue-derived stem cells. The journal of sexual medicine, 2010. 7(1 Pt 1): 
p. 89-98. 
www.intechopen.com
 
Erectile Dysfunction – Disease-Associated Mechanisms and Novel Insights into Therapy 
 
194 
[26] Bella, AJ., et al., Non-cell line induced autologous adult adipose tissue derived stem cells 
enhance recovery of erectile function in the rat following bilateral cavernous nerve crush 
injury. Sexual Medicine Society of  North America Meeting, 2008. 68p.  
www.intechopen.com
Erectile Dysfunction - Disease-Associated Mechanisms and Novel
Insights into Therapy
Edited by Dr. Kenia Nunes
ISBN 978-953-51-0199-4
Hard cover, 214 pages
Publisher InTech
Published online 29, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Erectile dysfunction is a widespread problem, affecting many men across all age groups and it is more than a
serious quality of life problem for sexually active men. This book contains chapters written by widely
acknowledged experts, each of which provides a unique synthesis of information on emergent aspects of ED.
All chapters take into account not only the new perspectives on ED but also recent extensions of basic
knowledge that presage directions for further research. The approach in this book has been to not only
describe recent popular aspects of ED, such as basic mechanism updates, etiologic factors and
pharmacotherapy, but also disease-associated ED and some future perspectives in this field.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Trevor Hardigan, R. Clinton Webb and Kenia Pedrosa Nunes (2012). Gene and Stem Cell Therapy in Erectile
Dysfunction, Erectile Dysfunction - Disease-Associated Mechanisms and Novel Insights into Therapy, Dr.
Kenia Nunes (Ed.), ISBN: 978-953-51-0199-4, InTech, Available from:
http://www.intechopen.com/books/erectile-dysfunction-disease-associated-mechanisms-and-novel-insights-
into-therapy/gene-and-stem-cell-therapy-in-erectile-dysfunction
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
